Polatuzumab Vedotin Biosimilar - Research Grade
Product Specifications
Background
Polatuzumab vedotin (Polivy) is an ADC consisting of a CD79b-directed antibody and Monomethyl auristatin E (MMAE) that can be used in combination with bendamustine and rituximab for the treatment of adult patients with at least two relapses or refractory diffuse large B-cell lymphoma. Polatuzumab vedotin binds to CD79b and is internalized by tumor cells. MMAE is cleaved from cells by lysosomal protease and promotes tumor cell apoptosis by inhibiting microtubule formation.
Product Name Alternative
MMAE
Host
CHO Cells
Reactivity
Human
Target
CD79b
Isotype
IgG1
Applications
Functional Assays
Concentration
1mg/mL
Purity
>90% by SDS-PAGE
Shipping Conditions
Room Temp
Storage Conditions
This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Formulation
25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
Applications Notes
Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC742853-500 1x 500 µL
CD54 / ICAM-1 (15.2), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC682453-500 1x 500 µL
HER-2 / c-erbB-2 / neu / CD340 (ERBB2/2453), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC742167-500 1x 500 µL
Emerin (Papillary Thyroid Carcinoma and EDMD Marker) (EMD/2167), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details